Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity Gets New York State Authorization for Systemic Lupus Erythematosus Test

NEW YORK — DxTerity said on Friday that it has received New York State authorization for its IFN-1 gene signature test for systemic lupus erythematosus (SLE).

The test determines levels of four mRNAs associated with type-1 interferon (IFN-1), a biomarker that indicates SLE disease severity and prognosis, by measuring expression levels of four associated genes. It is used to identify high-risk SLE patients who are less likely to respond to standard treatment and more likely to develop the kidney disease lupus nephritis.

With the authorization, the test is now available in all 50 US states, according to Rancho Dominguez, California-based DxTerity.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.